Table 2.
Summary of TESTEX assessment of study quality and reporting of included studies
| Study | Eligibility criteria specified | Randomisation specified | Allocation concealment | Groups similar at baseline | Blinding of assessor | Outcome measures assessed > 85% of participantsa | Intention to treat analysis | Between group statistical comparisons reportedb | Point measures and measures of variability reported | Activity monitoring in control group | Relative exercise intensity review | Exercise volume and energy expenditure | Overall TESTEX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Badrov et al. [27] | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 10 |
| Corriea et al. [28] | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 12 |
| Farah et al. [26] | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 10 |
| Gordon et al. [24] | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 10 |
| Gordon et al. [25] | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 10 |
| Nemoto et al. [15] | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 11 |
| Okamoto [16] | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 11 |
| Palmiera et al. [29] | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 10 |
| Punia et al. [14] | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 1 | 0 | 1 | 0 | 13 |
| Stiller-Moldovan et al. [30] | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 9 |
| Taylor et al. [31] | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 10 |
| Taylor et al. [24] | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 10 |
| Total | 12 | 12 | 4 | 12 | 4 | 25 | 9 | 24 | 12 | 0 | 12 | 0 | Median 10 |
Total out of 15 points
aThree points possible: 1 point, if adherence > 85%; 1 point, if adverse events reported; 1 point, if exercise attendance is reported
bTwo points possible: 1 point, if between-group statistical comparisons are reported for the primary outcome measure of interest; 1 point, if between-group statistical comparisons are reported for at least one secondary outcome measure